Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a deadly cancer, characterized by a uniquely immunosuppressive and fibrotic microenvironment responsible for its high chemoresistance. Jiang et al. identify FAK (focal adhesion kinase) activity as an interesting therapeutic target, the inhibition of which drastically reduces PDAC microenvironment deleterious features. In combination with gemcitabine and immune-checkpoint therapy, FAK inhibitor promotes long-term tumor stasis with extended survival in PDAC mouse models. In conclusion, Jiang et al. provide proof of concept that FAK inhibitors combined with chemotherapy will highly profit PDAC patients.